Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Waxman/Hatch Reinterpretation Underpins Change In 30-Month Stay Policy

Executive Summary

FDA's proposal to allow only one 30-month stay of approval for ANDAs hinges on a reinterpretation of Waxman/Hatch language declaring that patent holders must be notified if a generic application is amended to "include" a Paragraph IV certification

Related Content

FDA Chief Counsel Troy Resigns; Agency Says It Will Still Support Preemption
FDA Generics Rule: Agency Will Scrutinize Paragraph III Switches, Troy Says
Senate Generic Reform Bill Likely To Result In Earlier ANDA Filings
Blue Cross/Blue Shield Testing Generic Drug Ad Themes For 2003
Bristol Renounces Late-Listed Patents Under FTC Settlement
FDA Generics Review Staff To Increase 25% In President’s Budget Request
Product-By-Process Patents In Orange Book Should Claim Novel Products – FTC
Pfizer Glucotrol XL Patent Should Be Deemed Late Listed – Andrx
FDA Waxman/Hatch Policy Change Afforded Full White House Honors
FDA Patent Listing Criteria Allow Polymorph, Product-By-Process Claims



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts